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Background: To analyze a multi-institutional series of type C thymic carcinomas (TCs) (including neuroendocrine
tumors), focusing on the expression and mutations of c-KIT.
Materials and methods: Immunohistochemical expression of c-KIT/CD117, p63, CD5 and neuroendocrine markers,
as well as mutational analysis of c-KIT exons 9, 11, 13, 14, 17 by direct sequencing of 48 cases of TCs.
Immunohistochemical and molecular data were statistically crossed with clinicopathological features.
Results: Overall, 29 tumors (60%) expressed CD117, 69% were positive for CD5 and 85% (41 cases) for p63.
Neuroendocrine markers stained all six atypical carcinoids and five poorly-differentiated thymic squamous cell
carcinomas. Overall, six CD117-positive cases (12.5%) showed c-KIT mutation. No mutation was detected in CD117-
negative tumors and carcinoids. All the mutations were found in poorly-differentiated thymic squamous cell
carcinomas expressing CD117, CD5, p63 and lacking neuroendocrine markers (6 of 12 cases with these features).
Mutations involved exon 11 (four cases: V559A, L576P, Y553N, W557R), exon 9 (E490K) and exon 17 (D820E).
Conclusions: All TCs need an immunohistochemical screening with CD117, while c-KIT mutation analysis is
mandatory only in CD117-positive cases, particularly when coexpressing CD5 and p63, lacking neuroendocrine
differentiation. The finding of c-KIT mutation can predict efficacy with different c-KIT inhibitors.
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introduction
Thymic carcinomas (TCs) (type C) are rare malignant
neoplasms with poor prognosis and limited effective
therapeutic options [1–4]. More than half of TCs express
CD117, the product of the proto-oncogene c-KIT, while only
a subset of TCs harbor c-KIT mutations [5–14]. Previous works
have demonstrated the high frequency of CD117 expression in
TC (80%), whereas thymomas usually do not express CD117
and no c-KIT mutation has been detected in thymomas [5, 6, 8,
9, 11, 12]. Of note, different drugs acting as inhibitors of
receptor tyrosine kinases (RTKs) including c-KIT have
demonstrated a significant clinical benefit in selected patients
with c-KIT-mutated TC [7, 10, 12, 13].
The prevalence and the role of c-KIT mutations in a multi-
institutional series of consecutive CD117-positive and
CD117-negative TCs were here investigated. Based on our
own experience and on a review of the pertinent literature,
practical suggestions for a rationale use of RTK inhibitors in
TC are also provided.
materials and methods
Forty-eight TCs and thymic neuroendocrine tumors were retrospectively
collected from four different institutions (23 cases from Modena, 17 from
Reggio Emilia, 6 from Padova and 2 from Cremona). All the cases were
reviewed and reclassified as TCs (42 cases) and thymic neuroendocrine
tumors (6 cases, all of them with the features of atypical carcinoid),
according to the morphological criteria of the 2004-World Health
Organisation classification of thymic tumors [2]. The material consisted of
31 mediastinal biopsies (64.5%) and 17 surgical resections. Two cases
included in the present study have been previously published as case reports
[10, 14].
Clinicopathological data were recorded from the pathological reports
and the clinical charts. The following variables were registered in the
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present study: sex, age, histotype, immunohistochemical expression of
CD117, CD5, p63, chromogranin, synaptophysin and the presence of c-KIT
mutations. Patients’ survival was not considered in the study because of the
relatively limited number of cases with different tumor stage and with
variable therapeutic approaches.
The study was conducted in accordance with the precepts of the Helsinki
Declaration. According to the national laws, this study does not require any
ethical committee approval since all data were handled anonymously.
immunohistochemical analysis
In each case, 4-l thick sections were obtained from a representative block.
Sections were air dried overnight at 37C, then deparaffinized in xylene and
rehydrated through a decreasing concentration of alcohol to water.
Endogenous peroxidase activity was blocked by immersion for 10 min with
3% hydrogen peroxide (H2O2) in methanol. Incubation with primary
antibodies was accomplished with a modified streptavidin–biotin–peroxidase
technique using an automated immunostainer (Ventana Benchmark,
Tucson, AZ); 3#-3diaminobenzidine was used as the chromogene and
Harris’s hematoxylin as the counterstain. The panel of antibodies used in the
study and their technical characteristics are the following: CD117 (clone
A4502, Dakopatts, Glostrup, Denmark; 1 : 200 dilution without antigen
retrieval), CD5 (clone SP19, Ventana; prediluted with microwave antigen
retrieval), p63 (clone 4A4, NeoMarkers, Fremont, CA; 1 : 400 dilution with
microwave antigen retrieval), chromogranin (clone LK2H10, Ventana;
prediluted with microwave antigen retrieval) and synaptophysin (polyclonal,
Ventana; prediluted with microwave antigen retrieval).
Negative and positive controls were included in each batch. Negative
controls for specificity of staining were carried out by immunostaining
duplicate sections with nonimmune mouse IgG, at the same concentration
as that of the corresponding primary antibody.
A normal tonsil tissue was used as a positive control for CD117 (mast
cells), CD5 (T lymphocytes) and p63 (squamous epithelium), while
a pulmonary typical carcinoid serve as positive control for chromogranin
and synaptophysin. The percentage of positive cells and the intensity of
staining (0: negative; 1+: weak; 2+: moderate; 3+: strong) were recorded,
and a lesion was considered positive when at least 10% of the cells reacted
with a moderate or strong intensity on the relevant subcellular localization
(nuclear for p63, cytoplasmic for chromogranin and synaptophysin and
cytoplasmic/membranous for CD117 and CD5).
mutational analysis
Molecular analysis was carried out on formalin-fixed paraffin-embedded
tissues in 43 cases and on frozen samples in 5 cases. DNA content was
extracted from tumor cells. PCR was carried out in 20ll reactions containing
50–200 ng DNA, 2ll of commercial PCR buffer at final concentration 1X
(Applied Biosystems, Foster City, CA), 1.0–2.0 mM MgCl2, 400 lM of each
dNTP, 40 pmol of each primer and 3 units of AmpliTaq gold polymerase
(Applied Biosystems). PCR reaction was carried out on Uno II Thermoblock
(Biometra, Gottingen, Germany). Initial denaturation at 94C for 10 min was
followed by 41 cycles and by a final extension step (7 min at 72C). The cycles
included denaturation at 95C for 1 min, annealing at 53C–66C for 1 min
and extension at 72C for 2 min. The amplified DNA was electrophoresed on
2% agarose gel for 1 h at 110 V. The amplification products were then
purified by using MinElute PCR purification Kit (Qiagen, Hilden, Germany)
as indicated by the manufacturer’s instructions. PCR products were then
sequenced in both directions with ABI Prism BigDye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems), using the same primers as those
employed for PCR. Cycle sequencing products were finally purified by
Centri-Sep Spin Columns (Applied Biosystems) and subsequently runned on
the ABI Prism 310 automatic sequencer (Applied Biosystems). The data were
analyzed with the Sequencing Analysis 5.2 Software (Applied Biosystems).
The forward and reverse oligonucleotide primers used to amplify c-KIT exons
9, 11, 13, 14 and 17 are listed in supplemental Table S1 (available at Annals of
Oncology online).
statistical analysis
The correlation between clinicopathological variables,
immunohistochemical and molecular results was carried out using
contingency table methods and tested for significance using the Pearson’s
v2 test (SPSS version 16.0; Chicago Inc., Chicago, IL). A difference with
probability (P) values <0.05 was considered as significant.
results
Clinicopathological features are summarized in Table 1. Briefly,
the case series consisted of 26 males (54%) and 22 females with
a mean age of 61 years. Apart from 6 atypical carcinoids,
non-neuroendocrine TCs mainly consisted of squamous cell
histotype (38 cases) with poorly-differentiated morphology
(24 cases). Overall, 42 cases (87%) of the tumors were in
stage III or IV at diagnosis. Overall survival was available in
38 patients, ranging from 8 to 89 months (mean, 25 months).
Immunohistochemical and molecular characteristics are
summarized in Table 2. Of note, 29 cases (60%) showed
immunostaining for CD117 (all carcinoids and 23%/60.5% of
squamous cell carcinomas), while 33 cases (69%) were positive
with CD5 (32%/84% squamous cell carcinomas and
lymphoepithelioma-like carcinoma) and 41 cases (85%)
immunoreacted with p63 (all squamous cell carcinomas,
mucoepidermoid carcinoma, lymphoepithelioma-like
carcinoma and myoepithelial carcinoma) (Figure 1). Positive
staining with chromogranin and synaptophysin was observed in
all six atypical carcinoids and in one and four poorly-
differentiated thymic squamous cell carcinomas, respectively.
Table 1. Clinicopathologic characteristics of thymic neoplasms
Characteristics Cases (N = 48)
n (%)
Age Mean, 61 years; median 63.5
years (range, 34–84 years)
Sex
Male 26 (54)
Female 22 (46)
Type of material
Biopsy 31 (64.5)
Resection 17 (33.5)
Histotype
Squamous cell 38 (79)
Adenocarcinoma 1 (2)
Mucoepidermoid 1 (2)
Atypical carcinoid 6 (13)
Lymphoepitelioma like 1 (2)
Myoepithelial 1 (2)
Stage
II 6 (13)
III 11 (23)
IVA 20 (41)
IVB 11 (23)
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Overall, activating c-KIT mutations were observed in six
cases (12.5%). When considering only CD117-positive
neoplasms, the rate of c-KIT mutations raised to 21% (6 of 29
cases). Most important, despite positivity for CD117, no
mutation was detected in atypical carcinoids. Excluding
atypical carcinoids, the observed frequency of c-KIT mutations
in CD117-positive TCs was 26% (6 of 23 cases). All gene
alterations consisted of missense mutations in heterozygosis
involving exon 11 (four cases), exon 9 (one case) and exon 17
(one case). More in detail, mutations in exon 11 were V559A,
L576P, Y553N and W557R (supplemental Figure S1, available at
Annals of Oncology online): three of these mutations are
unprecedented in TCs, while L576P was previously found in
a poorly-differentiated TC [9]. Also the type of c-KIT mutation
detected in exon 9 (E490K) was not previously reported in TC
(supplemental Figure S1, available at Annals of Oncology online).
At statistical analysis, only CD117 expression was
significantly correlated with c-KIT mutations (P = 0.034). All
the 6 c-KIT-mutated cases were robustly positive (score 3+ in
>50% of tumor cells) for CD117. Among wild-type cases
(n = 42), 23 tumors stained with CD117, while 19 cases were
completely negative.
Finally, a striking relationship between morphology,
immunoprofile and c-KIT mutations was observed. All c-KIT-
mutated TCs consisted of poorly-differentiated squamous cell
carcinomas showing a solid growth of monomorphic cells with
moderate cytoplasm and nuclei with a single prominent
nucleolus dissected by bands of dense collagen. Tumor cells
strongly expressed CD117, CD5 and p63 but did not stain for
neuroendocrine markers. Taking in consideration only TCs
displaying these latter characteristics (12 cases overall), c-KIT
mutations were detected in half of the cases (6 cases).
discussion
TCs are aggressive neoplasms presenting as unresectable
mediastinal masses in the majority of the cases, with
multimodal chemoradiotherapy resulting often ineffective in
advanced stage [1, 2]. Despite TCs may show several genetic
alterations, no reliable molecular targets and relevant targeted
therapies have been so far identified [3, 15–17]. Among
different molecular pathways, a consistent body of evidence
suggests a critical role of the proto-oncogene c-KIT in TC [16,
17]. In fact, many TCs are characterized by high levels of c-KIT
protein transcripts and overexpression of CD117, the product
of c-KIT [5, 6]. This biomarker is very useful in the differential
diagnosis with thymomas and other mimicking neoplasms (i.e.
squamous cell carcinoma of the lung), which are typically
negative [5, 6]. Most importantly, in a subgroup of TCs, CD117
expression is related to a constitutive somatic activating c-KIT
mutation [7, 9, 10, 13, 14]. It is well known that, among
CD117-positive tumors [namely gastrointestinal stromal
tumors (GIST), small-cell lung cancer, seminoma, melanoma,
adenoid cystic carcinoma], only those showing c-KIT
mutations have a clinical benefit from selective c-KIT inhibitors
(i.e. imatinib, sunitinib, sorafenib) [18].
Several works have analyzed c-KIT mutations in thymomas
and TCs: results are summarized in Table 3 and supplemental
Table S2 (available at Annals of Oncology online). Pan et al. [5]
evidenced CD117 expression in 86% of TCs, but direct
sequencing of the c-KIT juxtamembrane (exons 9 and 11) and
tyrosine kinase (exons 13 and 17) domains failed to evidence
mutational alterations in 22 TCs. Similarly, Tsuchida et al. [9]
demonstrated CD117 immunostaining in 65% of 17 TCs, but
no mutations were detected in the 13 analyzed cases. Petrini
et al. [12] recently tested c-KIT mutations in eight TCs, five
thymomas and one TC cell line (T1889) by direct sequencing
Table 2. Immunohistochemical and molecular features of 48 thymic
carcinomas
Feature Cases (N = 48)
n (%)
CD117
Positive 29 (60)
Negative 19 (40)
CD5
Positive 33 (69)
Negative 15 (31)
p63
Positive 41 (85)
Negative 7 (15)
Synaptophysin
Positive 10 (21)
Negative 38 (79)
Chromogranin
Positive 7 (15)
Negative 41 (85)
c-KIT
Wild type 42 (87.5)
Mutated 6 (12.5)
Exon 11 (V559A, L576P, Y553N, W557R) 4 (66)
Exon 17 (D820E) 1 (17)
Exon 9 (E490K) 1 (17)
Figure 1. Example of poorly-differentiated thymic carcinoma
(A, haematoxylin–eosin staining ·200) expressing CD5
(B, immunohistochemistry ·200), p63 (C, immunohistochemistry ·200)
and CD117 (D, immunohistochemistry ·200).
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analysis from exon 1 to exon 20. Despite a significant
difference of CD117 expression between TCs (46%) and
thymomas (4%), the authors did not find c-KIT mutations
[12]. Of note, CD117 expression was observed only in primary
and not in relapsed tumors, but it was significantly associated
with a worse overall and progression-free survival [12]. Yoh
et al. [8] collected 24 thymomas and 17 TCs, detecting
epidermal growth factor receptor mutations in 2 thymomas
and a c-KIT missense mutation on exon 11 in 1 TC (L576P).
Finally, Girard et al. [11] evidenced 2 c-KIT mutated of 7
TCs (1 in exon 14, H697Y and 1 in exon 11, V560del). In
particular, the novel exon 14 missense mutation H697Y is
highly sensitive to sunitinib rather than imatinib. It is
noteworthy that all
c-KIT-mutated TCs consisted of squamous cell carcinoma
histotype with poorly-differentiated morphology (grade 3)
without keratinization.
Although prospective trials using imatinib in different
thymic malignancies have failed to demonstrate clinical
responses [17, 22, 24], a handful of case reports have yielded
promising results in selected patients [7, 10, 13, 14, 21].
In 2004, Strobel et al. [7] first reported a case of
a chemoresistant undifferentiated TC with exon 11 (V560del)
c-KIT mutation experiencing a stable disease for 6 months
using imatinib mesylate.
Subsequently, Bisagni et al. [10] reported a long-lasting
partial response in a TC showing a missense mutation on exon
17 (D820E). Based on the previous clinical experience dealing
with this kind of mutation in GIST, the authors decided to treat
the patient with sorafenib, a small molecule inhibiting several
targets, as c-KIT, PDGFRs, vascular endothelial growth factor
receptors (VEGFRs), FLT-3, c-RAF, B-RAF.
More recently, Disel et al. [13] reported a deletion mutation
on exon 11 (577–579del) in an advanced TC with squamous
features. The patient had a stable disease using sorafenib. Of note,
we are experiencing a consistent partial response (>8 months) in
a patient with a poorly-differentiated chemoresistant TC in
which a novel missense mutation on exon 11 (Y553N) was
detected [14]. The patient was treated with imatinib similarly to
what happens in GIST harboring the same mutation.
Other c-KIT mutations have been reported in TCs, involving
exon 11 (L576P) and exon 14 (H697Y). Supporting the critical
role of c-KIT mutations in TCs, no clinical responses have been
registered in ‘wild-type’ TCs treated with imatinib in recent
trials [17, 22, 24], although Hamada et al. [21] described
a clinical benefit in a wild-type thymic atypical carcinoid
treated with imatinib.
Other case reports have highlighted some effectiveness of
sorafenib [19], dasatinib [20] and somatostatin receptor-2 [25]
in TC or metastatic thymoma.
Strobel et al. [23] recently reported a partial response in four
patients with ‘wild-type’ TCs (three TCs with squamous cell
differentiation and one with undifferentiated TC), treated with
sunitinib. However, differently to imatinib, sunitinib is a multi-
targeted RTK inhibitor interfering with several targets, as c-KIT,
PDGFRs, VEGFRs, FLT-3, then also having an antiangiogenetic
role. In advanced GIST, sunitinib is adopted as second-line
therapy when the tumor develops resistance to imatinib and the
drug is particularly effective in GISTs harboring c-KIT mutations
on exon 13 and 17 or with PDGFR-alpha mutations [26].
Table 3. Summary of clinicopathological features of published thymic carcinomas with c-KIT mutations and/or treated with c-KIT inhibitors
Reference Age/sex Histologic type c-KIT mutation Stage Therapy Drug Clinical response
Strobel et al. [7] 54/M TC, squamous cell, G3 V560del ex11 Metastatic None Imatinib SD (6 months)
Bisagni et al. [10] 46/M TC, squamous cell, G3 D820E ex17 pT3, N2, M1 S + CT + RT Sorafenib PR (>15 months)
Disel et al. [13] 47/F TC, squamous cell, G3 del577-578–579 ex11 IVA CT + RT Sorafenib SD
Buti et al. [14] 48/M TC, squamous cell, G3 Y553N IV CT Imatinib PR (>8 months)
Li et al. [19] 46/M TC, squamous cell, G3 ND IV CT Sorafenib SD (>9 months)
Chuah et al. [20] NA Type-B2 ND I Imatinib + CT Dasatinib LR
Hamada et al. [21] Case 1: 62/M Atypical carcinoid None Invasive CT Imatinib Good clinical response
Case 2: 58/M Atypical carcinoid ND Invasive S + RT Nessuno Recurrence and metastasis
Giaccone et al. [22] Case 1: 36/M TC ND IVB CT Imatinib PD
Case 2: 67/M Type-B3 None IVA S + RT + CT Imatinib SD
Case 3: 47/M Type-B2/3 ND IVA CT Imatinib SD
Case 4: 76/M TC ND IVB None Imatinib PD
Case 5: 36/M TC ND IVB CT Imatinib PD
Case 6: 71/M TC None IVB None Imatinib PD
Case 7: 69/F TC, squamous cell type None IVB None Imatinib PD
Strobel et al. [23] Case 1: 35/M TC, squamous cell type None IVB CT + imatinib Sunitinib PR
Case 2: 69/M TC, squamous cell type None IVA S + RT + CT Sunitinib PR
Case 3: 77/M TC, squamous cell type None II S Sunitinib PR
Case 4: 28/F TC, undifferentiated None IVB CT + RT Sunitinib PR (2 months)
Palmieri et al. [24] 15 cases 4 type B2 None NA NA Imatinib PD
2 type B2/B3 None NA NA Imatinib PD
6 type B3 None NA NA Imatinib 1 SD
3 TC None NA NA Imatinib PD
CT, chemotherapy; F, female; G3, grade 3/poorly differentiated; M, male; NA, not available; ND, not done; PD, progression disease; PR, partial response; RT,
radiotherapy; S, surgery; SD, stable disease; TC, thymic carcinoma.
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Far from being a standard of care and in light of our data and
previous experiences with imatinib, sorafenib and sunitinib in
TC [7, 9, 10, 13, 14], a practical therapeutic algorithm based on
c-KIT mutation type was illustrated in Figure 2. Briefly, it
seems that the effective use of imatinib mesylate in TCs
significantly depends on the presence and type of c-KIT
mutation detected in tumor cells, this pharmacological agent
selectively inhibiting type III RTKs. On the other hand,
sorafenib and sunitinib are less selective than imatinib and can
be effectively adopted in TCs harboring imatinib-resistant c-
KIT mutations (i.e. involving exons 13, 14 and 17) or in wild-
type TCs due to their antiangiogenetic role, as suggested in the
recent preliminary experience of Strobel et al. [23].
conclusion
In our opinion, an immunohistochemical screening including
a small panel of antibodies (CD117, CD5, p63 and
neuroendocrine markers) is mandatory in all cases of TC. All
CD117-positive TCs should be tested for c-KIT mutations
expanding molecular test to exons 9, 11, 13, 14 and 17. The
probability to find mutations is higher in CD117-positive
thymic squamous cell carcinoma with poorly-differentiated
morphology on hematoxylin–eosin and with coexpression of
CD5 and p63 in absence of neuroendocrine markers. Mutations
involving c-KIT in TCs seem to possess the same biological
significance of those observed in GIST, and based on the
presence/absence and type of c-KIT mutation, TCs may benefit
of a targeted therapy with different RTK inhibitors.
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